Kilitch Drugs (India) Ltd
NSE:KILITCH
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
252.4
460.95
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Kilitch Drugs (India) Ltd
Income from Continuing Operations
Kilitch Drugs (India) Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
K
|
Kilitch Drugs (India) Ltd
NSE:KILITCH
|
Income from Continuing Operations
â‚ą106.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Income from Continuing Operations
â‚ą55.7B
|
CAGR 3-Years
47%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Cipla Ltd
NSE:CIPLA
|
Income from Continuing Operations
â‚ą43.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
23%
|
CAGR 10-Years
13%
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Income from Continuing Operations
â‚ą105.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
24%
|
CAGR 10-Years
5%
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Income from Continuing Operations
â‚ą41.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
19%
|
CAGR 10-Years
17%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Income from Continuing Operations
â‚ą17.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
29%
|
CAGR 10-Years
8%
|
See Also
What is Kilitch Drugs (India) Ltd's Income from Continuing Operations?
Income from Continuing Operations
106.3m
INR
Based on the financial report for Jun 30, 2024, Kilitch Drugs (India) Ltd's Income from Continuing Operations amounts to 106.3m INR.
What is Kilitch Drugs (India) Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
22%
Over the last year, the Income from Continuing Operations growth was 11%. The average annual Income from Continuing Operations growth rates for Kilitch Drugs (India) Ltd have been 22% over the past three years .